Literature DB >> 18462094

Management of methicillin-resistant Staphylococcus aureus bacteremia.

Sara E Cosgrove1, Vance G Fowler.   

Abstract

Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of infection and any associated complications. Evaluation for the presence of cardiac involvement is essential because inadequately managed S. aureus endocarditis is life threatening. Thus, physicians must aggressively negotiate treatment paths, considering whether the S. aureus bacteremia is complicated, whether foreign sources of infection should be removed or replaced, and whether surgical intervention is necessary. Selection of an antibiotic treatment is also an essential factor for optimal management. The increasing prevalence of methicillin-resistant S. aureus (MRSA) infections has created a tremendous demand for effective and safe antimicrobial agents other than the historic anti-MRSA agent vancomycin.

Entities:  

Mesh:

Year:  2008        PMID: 18462094     DOI: 10.1086/533595

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  Current trends in the management of cardiac implantable electronic device (CIED) infections.

Authors:  Emanuele Durante-Mangoni; Irene Mattucci; Federica Agrusta; Marie-Françoise Tripodi; Riccardo Utili
Journal:  Intern Emerg Med       Date:  2012-06-29       Impact factor: 3.397

2.  Screening cardiac surgery patients for MRSA: an economic computer model.

Authors:  Bruce Y Lee; Ann E Wiringa; Rachel R Bailey; Vishal Goyal; G Jonathan Lewis; Becky Y K Tsui; Kenneth J Smith; Robert R Muder
Journal:  Am J Manag Care       Date:  2010-07-01       Impact factor: 2.229

3.  Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates.

Authors:  Kati Seidl; Arnold S Bayer; Vance G Fowler; James A McKinnell; Wessam Abdel Hady; George Sakoulas; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

4.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.

Authors:  Marguerite L Monogue; Abrar K Thabit; Yukihiro Hamada; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Synergy: a cautionary tale.

Authors:  Donald P Levine
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

6.  Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs.

Authors:  Elisabeth Meyer; Frank Schwab; Barbara Schroeren-Boersch; Petra Gastmeier
Journal:  Intensive Care Med       Date:  2011-08-20       Impact factor: 17.440

7.  [Hospital-acquired pneumonia].

Authors:  K Tello; M J Richter; W Seeger; M Hecker
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-10-09       Impact factor: 0.840

8.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

9.  Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.

Authors:  Darin A Trier; Kimberly D Gank; Deborah Kupferwasser; Nannette Y Yount; William J French; Alan D Michelson; Leon I Kupferwasser; Yan Q Xiong; Arnold S Bayer; Michael R Yeaman
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

10.  In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies.

Authors:  O Gallon; C Guillet-Caruba; B Lamy; F Laurent; F Doucet-Populaire; J-W Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.